875-35-4

Basic information

• Product Name: 2,6-Dichloro-4-methylnicotinonitrile
• Synonyms: BUTTPARK 43\57-14;IFLAB-BB F0907-8363;3-PYRIDINECARBONITRILE, 2,6-DICHLORO-4-METHYL-;3-CYANO-2,6-DICHLORO-4-METHYLPYRIDINE;3-Cyano-4-methyl-2,6-dichloropyridine;2,6-DICHLORO-4-METHYL-3-CYANOPYRIDINE;2,6-DICHLORO-4-METHYLNICOTINONITRILE;2,6-DICHLORO-4-METHYLPYRIDINE-3-CARBONITRILE
• CAS NO: 875-35-4
• Molecular Formula: C₇H₄Cl₂N₂
• Molecular Weight: 187.03
• EINECS: 212-873-7
• Product Categories: Pyridine series;API intermediates;Pyridines;Chloropyridines;Halopyridines;C7 and C8Heterocyclic Building Blocks;Halogenated Heterocycles;Heterocyclic Building Blocks;Building Blocks;C7 to C18;C7 to C8;Chemical Synthesis;Halogenated Heterocycles;Heterocyclic Building Blocks
• Mol File: 875-35-4.mol

Chemical Properties

• Melting Point: 108-112 °C(lit.)
• Boiling Point: 118 °C / 5mmHg
• Flash Point: 145.5 °C
• Appearance: /
• Density: 1.42 g/cm³
• Vapor Pressure: 0.000395mmHg at 25°C
• Refractive Index: 1.574
• Storage Temp.: Store below +30°C.
• Solubility: 0.4g/l
• PKA: -4.53±0.10(Predicted)
• CAS DataBase Reference: 2,6-Dichloro-4-methylnicotinonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-Dichloro-4-methylnicotinonitrile(875-35-4)
• EPA Substance Registry System: 2,6-Dichloro-4-methylnicotinonitrile(875-35-4)

Safety Data

• Hazard Codes: T,Xi
• Statements: 20/21-25-37/38-41-43-36/37/38
• Safety Statements: 26-36/37/39-45-36
• RIDADR: UN 2811 6.1/PG 3
• WGK Germany: 3
• HazardClass: 6.1
• PackingGroup: III
• Hazardous Substances Data: 875-35-4(Hazardous Substances Data)

Usage

InChI:InChI=1/C7H4Cl2N2/c1-4-2-6(8)11-7(9)5(4)3-10/h2H,1H3

Synthetic route

2,6-dihydroxy-3-cyano-4-methylpyrimidine (5444-02-0) → 2,6-dichloro-4-methylnicotinonitrile (875-35-4)

Conditions	Yield
With trichlorophosphate at 200℃; for 7h;	98%
With trichlorophosphate at 180℃; for 6h;	92%
With trichlorophosphate at 180℃; for 6h; Sealed tube;	92%

3-cyano-4-methyl-6-hydroxypyrid-2-one (5444-02-0) → 2,6-dichloro-4-methylnicotinonitrile (875-35-4)

Conditions	Yield
With trichlorophosphate at 120℃; for 6h;	98%
With trichlorophosphate at 80℃; Temperature;	84%

3-ethynyl-4-methylpyridine-2,6-diol → 2,6-dichloro-4-methylnicotinonitrile (875-35-4)

Conditions	Yield
With trichlorophosphate at 180℃; for 6h; Sealed tube;	92%

C9H17N2(1+)*C7H5N2O2(1-) → 2,6-dichloro-4-methylnicotinonitrile (875-35-4)

Conditions	Yield
With benzyltrimethylammonium chloride; trichlorophosphate at 120℃; for 8h;	91%
With tetramethlyammonium chloride; trichlorophosphate for 8h; Reflux;	88%
With trichlorophosphate for 8h; Reflux;	50%

2-hydroxy-4-methyl-6-oxo-1,6-dihydropyridine-3-carbonitrile → 2,6-dichloro-4-methylnicotinonitrile (875-35-4)

Conditions	Yield
With N-benzyl-N,N,N-triethylammonium chloride; trichlorophosphate at 90℃; for 10h;	65%

1-butyl-6-hydroxy-4-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile (39108-47-9) → 2,6-dichloro-4-methylnicotinonitrile (875-35-4) + 1-butyl-6-chloro-1,2-dihydro-4-methyl-2-oxo-3-pyridinecarbonitrile (168697-58-3) + 1-butyl-2-chloro-1,6-dihydro-4-methyl-6-oxo-3-pyridinecarbonitrile

Conditions	Yield
With trichlorophosphate at 105℃; for 3h;	A 1% B 62% C 0.12 g

6-Chloro-4-methyl-2-oxo-1,2-dihydro-pyridine-3-carbonitrile → 2,6-dichloro-4-methylnicotinonitrile (875-35-4)

Conditions	Yield
With trichlorophosphate at 120℃;

(Z)-4-Butylcarbamoyl-2-cyano-3-methyl-but-2-enoic acid ethyl ester (1026543-43-0) → 2,6-dichloro-4-methylnicotinonitrile (875-35-4)

Conditions	Yield
Multi-step reaction with 2 steps 1: NaOH / 2 h / 140 °C 2: 1 percent / POCl3 / 3 h / 105 °C View Scheme

2,6-dihydroxy-3-cyano-4-methylpyrimidine (5444-02-0) + ethanolamine (141-43-5) → 2,6-dichloro-4-methylnicotinonitrile (875-35-4)

Conditions	Yield
With sodium carbonate; trichlorophosphate In quinoline

2,6-dichloro-4-methylnicotinonitrile (875-35-4) + 2-(4'-aminophenyl)ethyl alcohol (104-10-9) → 2,6-bis[4-(2-hydroxyethyl)phenylamino]-3-cyano-4-methylpyridine (631899-53-1)

Conditions	Yield
Stage #1: 2,6-dichloro-4-methylnicotinonitrile; 2-(4'-aminophenyl)ethyl alcohol With sodium carbonate at 120 - 195℃; for 18h; Stage #2: With hydrogenchloride In water	98%

2,6-dichloro-4-methylnicotinonitrile (875-35-4) → 2,6-dichloro-4-methyl-nicotinic acid (62774-90-7)

Conditions	Yield
With sulfuric acid; water; nitric acid at 70 - 105℃; for 2h;	96%
Multi-step reaction with 2 steps 1: 93 percent / aq. H2SO4 / 6 h / 98 °C 2: 88 percent / H2SO4; aq. NaNO2 / 20 - 25 °C View Scheme
Multi-step reaction with 2 steps 1: 66 percent / DIBALH / CH2Cl2; toluene / 2 h / -78 - 20 °C 2: 78 percent / NaClO2; NaH2PO4*2H2O / 2-methyl-propan-2-ol; H2O / 4 h / 10 - 25 °C View Scheme
With sulfuric acid; nitric acid at 110℃;
With sulfuric acid; nitric acid at 110℃;

2,6-dichloro-4-methylnicotinonitrile (875-35-4) → 6-hydrazinyl-4-methyl-2H-pyrazolo[3,4-b]pyridine-3-amine

Conditions	Yield
With hydrazine hydrate at 120℃; for 3h;	93.6%
With hydrazine

3-(2-ethylhexoxy)propylamine (5397-31-9) + 2,6-dichloro-4-methylnicotinonitrile (875-35-4) → C29H52N4O2 (861395-95-1)

Conditions	Yield
In water at 120℃; for 4h;	93.2%

2,6-dichloro-4-methylnicotinonitrile (875-35-4) → 2,6-dichloro-4-methyl-3-pyridinecarboxamide (38841-54-2)

Conditions	Yield
With sulfuric acid at 98℃; for 6h;	93%
With sulfuric acid at 80℃; for 4h;	91%
With sulfuric acid at 80℃; for 4h;	80.9%

2,6-dichloro-4-methylnicotinonitrile (875-35-4) → 3-cyano-4-methylpyridine (5444-01-9)

Conditions	Yield
With hydrogen; sodium acetate; palladium dichloride In methanol at 23℃; under 760.051 Torr; for 14h;	93%
With hydrogen; sodium acetate; palladium dichloride In methanol at 23℃; under 760.051 Torr; for 14h;	93%
With hydrogen; sodium acetate; palladium 10% on activated carbon In methanol at 20℃; for 16h;	86%
With ammonium hydroxide; zinc In tetrahydrofuran at 70℃; for 4h; Catalytic behavior; Reagent/catalyst; Solvent; Temperature; Large scale;	81%

2,6-dichloro-4-methylnicotinonitrile (875-35-4) → 2,6-diamino-4-methyl-3-pyridinecarbonitrile (38841-52-0)

Conditions	Yield
With ammonia at 150℃; for 16h;	91%
With ammonium hydroxide In dimethyl sulfoxide at 130℃; for 3h; Microwave irradiation;	67%

2,6-dichloro-4-methylnicotinonitrile (875-35-4) → 6-amino-2-chloro-4-methyl-3-pyridinecarbonitrile (51561-20-7)

Conditions	Yield
With ammonia In methanol at 150℃; Microwave irradiation; regioselective reaction;	90%
With ammonia In methanol at 150℃; for 0.416667h; Microwave irradiation;	45%

2,6-dichloro-4-methylnicotinonitrile (875-35-4) + methylhydrazine (60-34-4) → C9H14N6 (1352830-90-0)

Conditions	Yield
In 1,4-dioxane for 20h; Reflux;	89%

2,6-dichloro-4-methylnicotinonitrile (875-35-4) → 2-chloro-4-methyl-3-pyridinecarbonitrile (65169-38-2)

Conditions	Yield
With 5%-palladium/activated carbon; ammonium formate In methanol at 20℃; for 72h;	87%

2,6-dichloro-4-methylnicotinonitrile (875-35-4) + N,N-dimethyl-formamide dimethyl acetal (4637-24-5) → 2,6-dichloro-4-[(E)-2-(dimethylamino)ethenyl]pyridine-3-carbonitrile (1175559-53-1)

Conditions	Yield
In N,N-dimethyl-formamide at 100℃; for 2h;	86%
In isopropyl alcohol at 65℃; for 18h;	26%
In isopropyl alcohol at 65℃; for 18h;	26%

2,6-dichloro-4-methylnicotinonitrile (875-35-4) → 2,6-diazido-4-methylnicotinonitrile

Conditions	Yield
With sodium azide In water; N,N-dimethyl-formamide at 20℃; Solvent;	86%

3,5-dimethyl-1H-pyrazole (67-51-6) + 2,6-dichloro-4-methylnicotinonitrile (875-35-4) → 2,6-bis(3,5-dimethyl-1H-pyrazol-1-yl)-4-methyl-nicotinonitrile (935747-88-9)

Conditions	Yield
With sodium hydrogencarbonate; potassium iodide In N,N-dimethyl-formamide for 0.166667h; Microwave irradiation;	85.6%

2,6-dichloro-4-methylnicotinonitrile (875-35-4) + palladium dichloride → 3-cyano-4-methylpyridine (5444-01-9)

Conditions	Yield
With sodium acetate In methanol	85%

morpholine (110-91-8) + 2,6-dichloro-4-methylnicotinonitrile (875-35-4) → 2-chloro-4-methyl-6-morpholinonicotinonitrile

Conditions	Yield
In methanol at 0 - 20℃; Inert atmosphere;	85%
In methanol at 0 - 20℃; Inert atmosphere;	85%
In methanol at 0 - 20℃; Inert atmosphere;	85%
In methanol at 0 - 20℃; Inert atmosphere;	85%

cyclopentylzinc bromide lithium chloride + 2,6-dichloro-4-methylnicotinonitrile (875-35-4) → 2,6-dicyclopentyl-4-methylnicotinonitrile (1448351-74-3)

Conditions	Yield
With 1-methyl-1H-imidazole; Pd-PEPPSI-IPrAn In tetrahydrofuran; 1,4-dioxane at 0 - 80℃; for 6h; Negishi Coupling; Schlenk technique; Inert atmosphere;	81%

2,6-dichloro-4-methylnicotinonitrile (875-35-4) + 3-methoxypropylamine (5332-73-0) → 2-chloro-3-cyano-4-methyl-6-(3'-methoxypropylamino)-pyridine (56331-52-3)

Conditions	Yield
In ethanol at 90℃;	78%
With sodium carbonate In water; toluene
With triethylamine In toluene at 50℃; for 16h;

2-fluoro-5-methoxy-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)benzenesulfonamide + 2,6-dichloro-4-methylnicotinonitrile (875-35-4) → N-(4-(6-chloro-5-cyano-4-methylpyridin-2-yl)phenyl)-2-fluoro-5-methoxybenzenesulfonamide

Conditions	Yield
With dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2; caesium carbonate In 1,4-dioxane; water at 90℃; for 18h; Inert atmosphere;	78%

5-methoxypentan-1-amine (71259-63-7) + 2,6-dichloro-4-methylnicotinonitrile (875-35-4) → C13H18ClN3O

Conditions	Yield
In ethanol at 80℃;	78%

8-methoxyoctan-1-amine + 2,6-dichloro-4-methylnicotinonitrile (875-35-4) → C16H24ClN3O

Conditions	Yield
In ethanol at 100℃;	78%

2,6-dichloro-4-methylnicotinonitrile (875-35-4) + pinacol vinylboronate (75927-49-0) → 2-chloro-4-methyl-6-vinylnicotinonitrile

Conditions	Yield
With bis-triphenylphosphine-palladium(II) chloride; cesium fluoride In 1,4-dioxane; water at 85℃; for 12h; Suzuki Coupling; Inert atmosphere;	76%

2-Ethylhexylamine (104-75-6) + 2,6-dichloro-4-methylnicotinonitrile (875-35-4) → C23H40N4 (861396-01-2)

Conditions	Yield
In water at 130℃; for 4h;	75.6%

2,6-dichloro-4-methylnicotinonitrile (875-35-4) + 3-methoxypropylamine (5332-73-0) → 2,6-bis-(3'-methoxy-n-propylamino)-3-cyano-4-methylpyridine (51560-72-6)

Conditions	Yield
for 3h; Reflux;	75%
at 10 - 120℃; for 3h;	72.5%
at 10 - 20℃;	72.5%

4-fluoroboronic acid (1765-93-1) + 2,6-dichloro-4-methylnicotinonitrile (875-35-4) → 2-chloro-6-(4-fluorophenyl)-4-methylnicotinonitrile (943117-82-6)

Conditions	Yield
With tetrakis(triphenylphosphine) palladium(0); potassium carbonate In 1,4-dioxane; water at 100℃; for 3.5h; Suzuki Coupling; Inert atmosphere;	75%

2,6-dichloro-4-methylnicotinonitrile (875-35-4) + 3-amino-2-propanol (78-96-6, 1674-56-2) → C13H20N4O2 (845531-60-4)

Conditions	Yield
In water at 130℃; for 3h;	74.5%
at 120℃; for 3h;	74.6%

2,6-dichloro-4-methylnicotinonitrile (875-35-4) + N,N-dimethylethylenediamine (108-00-9) → 2-(2-dimethylaminoethylamino)-3-cyano-4-methyl-6-chloropyridine + 2-chloro-6-(2-(dimethylamino)ethylamino)-4-methylnicotinonitrile

Conditions	Yield
In ethanol at 20℃; for 48h;	A n/a B 68%

Upstream product

• 5444-02-0 2,6-dihydroxy-3-cyano-4-methylpyrimidine 
• 39108-47-9 1-butyl-6-hydroxy-4-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile 
• 5444-02-0 3-cyano-4-methyl-6-hydroxypyrid-2-one 
• 141-43-5 ethanolamine 
• 1026543-43-0 (Z)-4-Butylcarbamoyl-2-cyano-3-methyl-but-2-enoic acid ethyl ester 

Downstream Products

• 52982-90-8 2-amino-6-chloro-4-methyl-3-pyridinecarbonitrile 
• 51561-20-7 6-amino-2-chloro-4-methyl-3-pyridinecarbonitrile 
• 38841-52-0 2,6-diamino-4-methyl-3-pyridinecarbonitrile 
• 38841-54-2 2,6-dichloro-4-methyl-3-pyridinecarboxamide 
• 51564-29-5 2-chloro-6-methoxy-4-methylpyridine-3-carbonitrile 
• 243469-65-0 6-chloro-2-methoxy-4-methylnicotinonitrile 
• 149379-71-5 2-methoxy-4-methylpyridine-3-carbonitrile 
• 243469-66-1 6-methoxy-4-methylpyridine-3-carbonitrile 
• 91591-70-7 2,6-dichloro-4-methyl-3-pyridinecarboxaldehyde 
• 62774-90-7 2,6-dichloro-4-methyl-nicotinic acid 
• 220559-34-2 methyl 4.6-dichloro-3-(diethylamino)furo[3,4-c]pyridine-1-carboxylate 
• 243469-62-7 3-hydroxymethyl-2-methoxy-4-methylpyridine 
• 243469-67-2 4-(2-hydroxy-2-phenylethyl)-2-methoxypyridine-3-carbonitrile 
• 243469-68-3 methanesulfonic acid 2-(3-cyano-2-methoxy-pyridin-4-yl)-1-phenyl-ethyl ester 

Relevant articles and documents

Preparation method for nitrobenzisothiazole-pyridine dye with good acid-base stability

The invention discloses a preparation method for a nitrobenzisothiazole-pyridine dye with good acid-base stability. The preparation method comprises the following steps: (1) preparing a compound (i) from 1,4-dimethyl-3-cyano-6-hydroxy-2-pyridone and phosphorus oxychloride; (2) preparing a compound (ii) from the compound (i) and NH2-(CH2)n-O-CH3; (3) preparing a compound (A) from the compound (ii)and NH2-(CH2)n-O-CH3; (4) diazotizing 3-amino-5-nitrobenzoisothiazole by using sodium nitrite so as to obtain diazonium salt; (5) mixing the diazonium salt with the compound (A) for a reaction, and carrying out aging so as to obtain a crude product; and (6) dissolving the crude product, carrying out cooling extraction, and carrying out purifying so as to obtain a compound as shown in a structuralformula (B) which is described in the specification. According to the invention, the nitrobenzisothiazole-pyridine dye with good acid-base stability is synthesized in a functional group conversion mode; and the preparation method provided by the invention is easily-controllable in reaction conditions, simple in operation and high in product yield.

Design, Synthesis, and Pharmacological Evaluation of Second Generation EZH2 Inhibitors with Long Residence Time

Histone methyltransferase EZH2, which is the catalytic subunit of the PRC2 complex, catalyzes the methylation of histone H3K27 - a transcriptionally repressive post-translational modification (PTM). EZH2 is commonly mutated in hematologic malignancies and frequently overexpressed in solid tumors, where its expression level often correlates with poor prognosis. First generation EZH2 inhibitors are beginning to show clinical benefit, and we believe that a second generation EZH2 inhibitor could further build upon this foundation to fully realize the therapeutic potential of EZH2 inhibition. During our medicinal chemistry campaign, we identified 4-thiomethyl pyridone as a key modification that led to significantly increased potency and prolonged residence time. Leveraging this finding, we optimized a series of EZH2 inhibitors, with enhanced antitumor activity and improved physiochemical properties, which have the potential to expand the clinical use of EZH2 inhibition.

The Guareschi-Thorpe Cyclization Revisited - An Efficient Synthesis of Substituted 2,6-Dihydroxypyridines and 2,6-Dichloropyridines

DBU as base is key in a practical modified Guareschi-Thorpe cyclization of β-keto esters and 2-cyanoacetamide to allow the synthesis of substituted pyridones in good to excellent yields. The chlorination of DBU salts of pyridones with POCl 3 in the presence of a quaternary ammonium salt under standard atmospheric reflux conditions as opposed to the typical pressure equipment led to high yields of substituted 2,6-dichloropyridines.

Preparation method for nevirapine intermediate

The invention provides a preparation method for a nevirapine intermediate. The preparation method comprises: performing a cyclization reaction of ammonia water, methyl cyanoacetate and methyl acetoacetate to form a compound hydroxyl: 2,6-dihydroxy-3-cyano-4-methylpyridine; adding triethylamine dropwise, introducing chlorine gas at the temperature until the reaction is complete, and obtaining 2,6-dichloro-3-cyano-4-methylpyridine; adding concentrated sulfuric acid, heating to 120 DEG C to react for 3-5 h, and then cooling to 60 DEG C; adding water to perform hydrolysis reaction, and obtaining 2,6-dichloro-3-amido-4-methylpyridine; adding a degradation reagent sodium hypochlorite, and obtaining a nevirapine intermediate 2,6-dichloro-3-amino-4- methylpyridine by Hofmann reaction. According tothe preparation method, commonly used phosphorus oxychloride is replaced with the directly introduced chlorine gas, which solves the problems that the wastewater content is too high, it is difficultto perform treatment and the odor of phosphorus oxychloride is bad, and the one-time yield of the product is 90.1%.

Wnt SIGNALING INHIBITOR, COMPOSITION, AND COMPOUND AS USE THEREFOR

PROBLEM TO BE SOLVED: To provide an inhibitor for Wnt signaling route. SOLUTION: The present invention provides a compound represented by formula I, and a composition comprising the compound (X1-X8 independently represent CR4 or N; Y1 is H or C (R4)3; Y2 and Y3 independently represent H, halogen or C (R3)3; R1 and R2 independently represent H, halogen, C1-6 alkyl, quinolinyl or the like; R3s independently represent H, halogen, cyano, C1-6 alkyl or the like; R4s independently represent H, halogen, cyano, C1-6 alkoxy or the like). SELECTED DRAWING: None COPYRIGHT: (C)2017,JPOandINPIT

Inhibiting WNT signal conduction of compound, composition and use thereof (by machine translation)

The invention relates to a having the general formula (1) compounds and compositions thereof, and the use of the compound or composition thereof to inhibit WNT signal transmission method. The compounds of this invention and its composition can effectively inhibit the secretion of WNT protein, inhibit WNT signal conduction, so the WNT-mediated disease with a very good therapeutic effect. . (by machine translation)

TUMOR BIOMARKERS AND USE THEREOF

Disclosed herein are biomarkers related to WNT signal transduction pathway, as well as methods and kits comprising the same. Further, the present disclosure relates to the use of the biomarkers in patient selection, companion diagnostics, and treatment of cancer.

Compound as WNT Signaling Inhibitor, Composition, and Use Thereof

The present invention relates to a compound having the structure of Formula I as inhibitor of WNT signal transduction pathways, as well as a composition comprising the compound. Further, the present invention relates to the use of the compound and the method of inhibiting the WNT signal transduction pathways.

COMPOUNDS FOR TREATMENT OF CANCER

The present invention relates to compounds as inhibitor of WNT signal transduction pathway, as well as a composition comprising the same. Further, the present invention relates to the use of the compounds in the treatment of cancer.

AZAINDENOISOQUINOLINE TOPOISOMERASE I INHIBITORS

The invention described herein pertains to substituted azaindenoisoquinoline compounds, in particular 7-, 8-, 9-, and 10-azaindenoisoquinoline compounds, which are inhibitors of topoisomerase I, processes and intermediates for their syntheses, pharmaceutical compositions of the compounds, and methods of using them in the treatment of cancer.